Exact Sciences Corporation


SKU: EXAS-1 Category:


Exact Sciences Corporation delivered a positive result and managed an all-around beat in the quarter. In the third quarter, the company reported a robust revenue of $628 million, showcasing a remarkable 20% growth or 23% on a core basis. The Screening segment, with revenues reaching $472 million, experienced a notable 31% surge, driven by the widespread adoption of Cologuard. This momentum was attributed to commercial productivity and strong relationships with payers and providers. During the quarter, over 10,000 new healthcare professionals ordered Cologuard, contributing to a total of more than 331,000 orders since its launch. Precision and Oncology revenue increased, primarily led by a 14% global expansion of Oncotype DX. The company closed the quarter with cash and securities totaling $734 million. Looking ahead, Exact Sciences raised its total revenue guidance for the year to a range of $2.476 billion to $2.486 billion. This forecast includes Screening revenue between $1.848 billion and $1.853 billion, Precision Oncology revenue between $622 million and $627 million, and COVID revenue of $6 million, considering the discontinuation of COVID testing in July. The Exact Sciences platform, designed for sustainable double-digit revenue growth and margin improvement, is well-positioned to meet long-term financial targets based on the progress made throughout the year.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!